Information Provided By: 
Fly News Breaks for August 26, 2016
CERS
Aug 26, 2016 | 14:13 EDT
Cantor analyst Bryan Brokmeier says investors should buy shares of Cerus following the FDA's revised industry guidance recommending all blood centers across the U.S. implement either blood testing for the Zika Virus or FDA approved pathogen-reduction technology, of which the company has the only available technology. Further, the analyst believes this is a "big step" toward accelerated adoption of Cerus' INTERCEPT platform. Brokmeier reiterates a Buy rating and $9 price target on the shares.
News For CERS From the Last 2 Days
There are no results for your query CERS
